Massive hypertriglyceridemia associated with paclitaxel; a case report

This report describes a patient who developed massive hypertriglyceridemia (12,488 mg/dL or 141 mmol/L) during paclitaxel and carboplatin adjuvant chemotherapy for high grade serous fallopian tube carcinoma. Paclitaxel was thought to be the causative agent and she had normal triglyceride levels foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Koneshamoorthy, Anojian, Hulse, Danielle, Yuen Chong, Chia, Krishnamurthy, Balasubramanian, Ananda, Sumitra, Hamblin, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241137/
https://www.ncbi.nlm.nih.gov/pubmed/35782104
http://dx.doi.org/10.1016/j.gore.2022.101030
Descripción
Sumario:This report describes a patient who developed massive hypertriglyceridemia (12,488 mg/dL or 141 mmol/L) during paclitaxel and carboplatin adjuvant chemotherapy for high grade serous fallopian tube carcinoma. Paclitaxel was thought to be the causative agent and she had normal triglyceride levels following a change to carboplatin and gemcitabine. To our knowledge, this is the highest reported triglyceride level associated with paclitaxel. Measurement of serum lipids should be considered in individuals receiving taxane chemotherapy, especially in those with type 2 diabetes mellitus or a history of dyslipidemia.

Ejemplares similares